CULVER CITY, Calif., February 19, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded ...
ImmunityBio, Inc. (NASDAQ:IBRX) surged by 16.42 percent on Wednesday to end at $3.9 apiece as investors cheered news that it was authorized by the Food and Drug Administration (FDA) to help ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Pre-market: 6:45:55 am GMT-5 ...
Pre-market: 7:14:14 am GMT-5 ...
Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
Hosted on MSN6d
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz IntensifiesShares of ImmunityBio Inc. surged 16.4% on Wednesday, marking their best session in over a month, and extended gains in after ...
After hours: 7:50:30 p.m. EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback